Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,486 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): A Phase Ib Dose-Escalation Study of Venetoclax Combined With Modified Intensive Chemotherapy.
Chua CC, Roberts AW, Reynolds J, Fong CY, Ting SB, Salmon JM, MacRaild S, Ivey A, Tiong IS, Fleming S, Brown FC, Loo S, Majewski IJ, Bohlander SK, Wei AH. Chua CC, et al. Among authors: fleming s. J Clin Oncol. 2020 Oct 20;38(30):3506-3517. doi: 10.1200/JCO.20.00572. Epub 2020 Jul 20. J Clin Oncol. 2020. PMID: 32687450 Clinical Trial.
Author reply: To PMID 22757980.
Wei A, Fleming S. Wei A, et al. Among authors: fleming s. Intern Med J. 2014 Aug;44(8):825. doi: 10.1111/imj.12506. Intern Med J. 2014. PMID: 25081054 No abstract available.
Comparison of biosimilar filgrastim with originator filgrastim for peripheral blood stem cell mobilization and engraftment in patients with multiple myeloma undergoing autologous stem cell transplantation.
Pham T, Patil S, Fleming S, Avery S, Walker P, Wei A, Curtis D, Stuart G, Klarica D, O'Brien M, Morris K, Das T, Bollard G, Muirhead J, Coutsouvelis J, Spencer A. Pham T, et al. Among authors: fleming s. Transfusion. 2015 Nov;55(11):2709-13. doi: 10.1111/trf.13233. Epub 2015 Jul 14. Transfusion. 2015. PMID: 26173921
The mTOR inhibitor everolimus in combination with azacitidine in patients with relapsed/refractory acute myeloid leukemia: a phase Ib/II study.
Tan P, Tiong IS, Fleming S, Pomilio G, Cummings N, Droogleever M, McManus J, Schwarer A, Catalano J, Patil S, Avery S, Spencer A, Wei A. Tan P, et al. Among authors: fleming s. Oncotarget. 2016 Nov 29;8(32):52269-52280. doi: 10.18632/oncotarget.13699. eCollection 2017 Aug 8. Oncotarget. 2016. PMID: 28881728 Free PMC article.
High expression of HMGA2 independently predicts poor clinical outcomes in acute myeloid leukemia.
Marquis M, Beaubois C, Lavallée VP, Abrahamowicz M, Danieli C, Lemieux S, Ahmad I, Wei A, Ting SB, Fleming S, Schwarer A, Grimwade D, Grey W, Hills RK, Vyas P, Russell N, Sauvageau G, Hébert J. Marquis M, et al. Among authors: fleming s. Blood Cancer J. 2018 Jul 19;8(8):68. doi: 10.1038/s41408-018-0103-6. Blood Cancer J. 2018. PMID: 30061630 Free PMC article.
Correction: High expression of HMGA2 independently predicts poor clinical outcomes in acute myeloid leukemia.
Marquis M, Beaubois C, Lavallée VP, Abrahamowicz M, Danieli C, Lemieux S, Ahmad I, Wei A, Ting SB, Fleming S, Schwarer A, Grimwade D, Grey W, Hills RK, Vyas P, Russell N, Sauvageau G, Hébert J. Marquis M, et al. Among authors: fleming s. Blood Cancer J. 2019 Feb 28;9(3):28. doi: 10.1038/s41408-019-0190-z. Blood Cancer J. 2019. PMID: 30820024 Free PMC article.
1,486 results